Introduction
ND (see Glossary) is a rare disorder with a prevalence of around 1 in 100 000-200 000 live births. [ 4 4 7 _ T D $ D I F F ] 1 in 1001 in 100 It is characterized by diabetes that usually presents within the first 6 months of life. ND is caused by mutations in several different genes but those in the genes encoding the pore-forming (Kir6.2, KCNJ11) and regulatory (SUR1, ABCC8) subunits of the [ 4 4 8 _ T D $ D I F F ] KK ATP channel channel are the most common (50% of cases) and are the focus of this review.
The K ATP channel [ 4 4 9 _ T D $ D I F F ] plays a key role in insulin release from pancreatic beta cells because it links cell metabolism to electrical activity [1] . It does so by regulating the beta cell resting membrane potential. At low glucose levels, channel activity is high, which hyperpolarizes the beta cell and switches off electrical activity and insulin secretion [1] . Elevation of extracellular glucose increases glucose uptake and metabolism and stimulates ATP production at the expense of ADP. These nucleotide changes result in closure of the K ATP channel, triggering membrane ; its further closure also contributes to the graded increase in action potential firing and insulin secretion at glucose concentrations above threshold [2] .
Activating mutations in either Kir6.2 or SUR1 that reduce the ability of metabolically generated ATP to close the channel prevent glucose-induced electrical activity and insulin release, resulting in ND [3] [4] [5] . However, most mutant channels can be closed by sulfonylurea drugs, such as glibenclamide (glyburide) [6] . These are now the treatment of choice for ND, because they improve the patient's clinical condition and quality of life, and reduce medical costs [7, 8] .
In this review, we provide an overview of recent advances in our understanding of the molecular mechanisms underlying K ATP channel ND, and its treatment with sulfonylureas.
Activating K ATP Channel Mutations Cause ND
The K ATP channel is a large octameric complex comprising a central Kir6.2 tetramer, surrounded by four SUR1 subunits, as can be seen in the recent 6-Å resolution cryo-electron microscopy (EM) structure [9, 10] (Figure 1 ). Activating mutations in the K ATP channel produce a range of phenotypes that correlate with the extent of reduction in channel ATP sensitivity [4, 11] . At one end of the spectrum are mutations that cause a small decrease in ATP inhibition. These produce permanent (PNDM) or transient ND (TNDM) [3, 4, 12, 13] , lead to diabetes in young adult life [14] [15] [16] . At the other end of the spectrum are mutations that render the channel highly insensitive to ATP and cause neurological complications in addition to diabetes [4, 18] . Thus, the greater the decrease in channel ATP sensitivity, the more severe the clinical phenotype.
Most ND mutations occur spontaneously. Kir6.2 mutations are almost all heterozygous and most frequently occur at residues R201 and V59 [11] , whereas SUR1 mutations are genetically more heterogeneous [11, 19] All ND mutations reduce the ability of ATP to cause channel closure. However, mechanistically, they act in a variety of ways. They may impair ATP binding at Kir6.2 or the way in which ATP binding is translated into pore closure [23] [24] [25] . They may enhance MgADP activation at SUR1 by increasing the affinity of the nucleotide-binding domains (NBDs) for nucleotides [26] . In addition, mutations in either Kir6.2 or SUR1 may increase the unliganded channel open probability, which leads to a decrease in both ATP and sulfonylurea block [18, 27] . depolarization, electrical activity, calcium influx, and insulin release. They have been used for >50 years to treat T2DM [6] , and are now the therapy of choice for K ATP channel-dependent ND [7, 28] . Higher drug concentrations are often needed in patients with ND than in those with T2DM: the usual dose for an adult with T2DM is 0.08-0.25 mg/kg/day, whereas patients with Glossary [7] . [7] . Conseqently, it is expected that patients will be less likely to develop diabetic complications. Third, despite the improved glucose control, there is no change in incidence of In marked contrast to T2DM, where sulfonylureas eventually fail to control glycemia, a common feature of sulfonylurea therapy in ND is that the drug dose declines with time after transfer from insulin [6] . This may reflect a time-dependent improvement in beta cell function and/or mass, because 
Sulfonylurea Therapy in ND

Insights into the Molecular Mechanism of Sulfonylurea Action
Sulfonylureas interact with two sites on the K ATP channel, a high-affinity site on SUR1 and a lowaffinity site on Kir6.2 [ 4 7 3 _ T D $ D I F F ] [6, 41] , but only the former is of therapeutic importance. The location of the sulfonylurea-binding site on SUR1 is still unknown, but mutagenesis studies indicate that it involves residues in the third and eighth cytosolic loops. These regions come into close apposition in the recent 6-Å cryoEM structure of the K ATP channel [9, 10] , suggesting a possible site for the sulfonylurea-binding pocket ( Figure 1B The fact that sulfonylurea inhibition is incomplete for channels containing severe ND mutations (due to their impaired ATP sensitivity), explains why patients with these mutations are less stimulates channel activity at SUR1 and inhibits it at Kir6.2. Thus, channel activity is a balance between these inhibitory and stimulatory effects (A). Sulfonylureas both block channel activity directly (by a maximum of 50-80%) and prevent MgATP activation (B). Consequently, ATP inhibition is no longer counteracted by MgATP activation. Thus, ATP and sulfonylurea block now summate to produce complete channel inhibition (B). Channels with mutations that reduce ATP block (e.g., G334D) are activated, but not blocked, by MgATP (C). Sulfonylureas still both block channel activity and prevent MgATP activation (D). However, the overall block of channel activity is less than for wildtype channels because of lack of ATP block at Kir6. Transfer to sulfonylurea therapy restores meal-stimulated insulin release [7] and decreases fluctuations in blood glucose [ 4 5 9 _ T D $ D I F F ] [31, 32] . Restoration of the beta cell incretin response and the amplifying effects of glucose likely contribute to these important effects. Incretins are released in response to the presence of food in the gut and exert a stimulatory effect on insulin secretion, reducing the excursion in blood glucose. However, both incretins (e.g., GLP-1) and paracrine hormones (e.g., glucagon) only potentiate insulin secretion induced by glucose. They do not initiate insulin release because they are only effective once intracellular calcium has been elevated by glucose-stimulated K ATP channel closure [3] . Therefore, they are ineffective in patients with insulin-treated ND, but become effective following transfer to sulfonylureas [7] . Likewise, the amplifying effects of glucose on insulin secretion Given that their diabetes is so well controlled, some patients with ND elect to remain on drug therapy when pregnant. Good [ 4 4 4 _ T D $ D I F F ] glycemic control is important for both mother and fetus. However, glibenclamide can cross the placenta and, as a consequence, fetuses who do not carry a ND mutation may require early delivery, and develop fetal macrosomia and/or postnatal [ 4 9 2 _ T D $ D I F F ] hyperinsulinemic hypoglycemia [54] [55] [56] . Thus, sulfonylurea therapy should be avoided (at least during the third trimester) if prenatal genetic testing has not been performed or if the fetus is found not to carry the mutation. Non-invasive prenatal genetic testing in the offspring of a father with ND has been successfully performed [ 4 9 3 _ T D $ D I F F ] [57] . By contrast, if the fetus does carry the mutation, sulfonylureas may be beneficial, because they can be expected to prevent the low birth weight [7, 19] , caused by reduced fetal insulin secretion in utero [ 4 9 4 _ T D $ D I F F ] that is characteristic of ND neonates.
Why Do Some Patients Not Respond to Sulfonylureas?
Not all patients respond to sulfonylurea therapy. Whether they do so depends on the specific mutation they and it is unlikely that they would be able to transition even if the drug dose were greatly increased.
There are also several mutations for which some patients transferred and others failed to do so, despite taking an adequate dose of sulfonylureas [ 4 9 6 _ T D $ D I F F ] [33, 59 ]. This appears to be related to the duration of diabetes. Almost all individuals who started taking sulfonylureas during the first 5 years after diabetes diagnosis transferred successfully, whereas only 65% of those over the age of 18 were able to do so Why Is ND Sometimes Transient? In some patients with ND, diabetes is transient, remitting within a few months or years of birth [4, 11, 12] . Why diabetes remits is unclear. One possibility is that it reflects a reduced insulin demand or improved beta cell function at the time of remission. Why many TNDM patients subsequently relapse also remains unknown, but might, in part, result from the increase in insulin resistance that normally develops at puberty 
ND Mutations Can Cause Neurological Problems
K ATP channels (Kir6.2/SUR1) are not confined to beta cells; they are found in many other tissues, including muscle and brain. This accounts for the fact that approximately 20% of patients with ND have profound neurological deficits. These include delayed motor and mental development, attention deficit, hyperactivity, autism, aggression, intellectual disability, and (occasionally) ) might be more effective remains to be tested. Given that K ATP channel activation appears to decrease inhibitory tone, drugs that decrease GABA uptake or prolong its action might also be worth exploring.
An alternative explanation for the poor effects of sulfonylureas on cognitive function is that K ATP channel overactivity in the developing brain produces irreversible structural effects. Although gross changes in brain anatomy are not observed, it is possible that the enhanced K ATP current prevents synaptic connections from forming correctly. . Furthermore, the functional importance of SUR1 in the human heart remains unclear, and the lack of obvious changes in cardiac function in patients with ND suggests that its contribution is small.
Does ND Offer Insight into T2DM Etiology?
Given that activating K ATP mutations cause ND, can mutations that produce a lesser decease in ATP sensitivity cause diabetes in later life? The answer appears to be yes. It is important to appreciate that, because the K ATP channel dominates the beta cell membrane potential, its closure causes a large increase in the input resistance of the membrane. Ohm's law dictates that, when the membrane resistance is high, tiny changes in current will lead to marked changes in membrane potential. One should also bear in mind that, below the threshold for electrical activity, there will be no insulin secretion. Above it, insulin release will be initiated. Thus, even a tiny change in K ATP current may suffice to make the difference between electrical silence and action potential firing (depending on the input resistance and the membrane potential). This explains why tiny changes in K ATP current (or ATP sensitivity), which can be very hard to measure, can markedly affect insulin secretion. 
Concluding Remarks and Future Perspectives
ND provides a paradigm for how understanding the pathophysiology of a disease can improve therapy for affected patients. It is an excellent example of pharmacogenomics, illuminating the beneficial effects of tailoring therapy to a patient's individual genetic make-up. Functional studies have revealed why some mutations produce a more severe clinical phenotype and why some patients respond to drug therapy whereas others do not. Conversely, ND has provided novel insights into the physiological role of the K ATP channel. Nevertheless, many questions remain (see Outstanding Questions). We still lack an understanding of precisely how nucleotides and drugs regulate channel activity, how chronic [ 4 4 6 _ T D $ D I F F ] hyperglycemia impairs beta cell mass and/or function, why diabetes is transient is some patients, and what causes the neurological deficits. Answers to these questions will illuminate our understanding [ 5 3 5 _ T D $ D I F F ] not only of neonatal diabetes, but also of its far more common relative, T2DM. They will also provide fresh insight into the role of the K ATP channel in tissues other than the beta cell. 
